Literature DB >> 12704192

Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect.

Ju-Ock Nam1, Jung-Eun Kim, Ha-Won Jeong, Sung-Jin Lee, Byung-Heon Lee, Je-Yong Choi, Rang-Woon Park, Jae Yong Park, In-San Kim.   

Abstract

betaig-h3 is an extracellular matrix protein that mediates adhesion and migration of several cell types through interaction with integrins. In the present study, we tested whether betaig-h3 mediates endothelial cell adhesion and migration, thereby regulating angiogenesis. In this study, we demonstrate that not only betaig-h3 itself but also all four fas-1 domains of betaig-h3 mediate endothelial cell adhesion and migration through interaction with the alphavbeta3 integrin. We found that the alphavbeta3 integrin-interacting motif of the four fas-1 domains of betaig-h3 is the same YH motif that we reported previously to interact with alphavbeta5 integrin. The YH peptide inhibited endothelial cell adhesion and migration in a dose-dependent manner. We demonstrate that the YH peptide has anti-angiogenic activity in vitro and in vivo using an endothelial cell tube formation assay and a Matrigel plug assay, respectively. Our results reveal that betaig-h3 bears alphavbeta3 integrin-interacting motifs that mediate endothelial cell adhesion and migration and, therefore, may regulate angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704192     DOI: 10.1074/jbc.M300358200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Viral infection and human disease--insights from minimotifs.

Authors:  Krishna Kadaveru; Jay Vyas; Martin R Schiller
Journal:  Front Biosci       Date:  2008-05-01

2.  T-CAM, a fastatin-FIII 9-10 fusion protein, potently enhances anti-angiogenic and anti-tumor activity via alphavbeta3 and alpha5beta1 integrins.

Authors:  Ju-Ock Nam; Mi-Yeon Jung; Narendra Thapa; Byung-Heon Lee; Rang-Woon Park; In-San Kim
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

3.  Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Authors:  Pubudu M Peiris; Aaron Abramowski; James Mcginnity; Elizabeth Doolittle; Randall Toy; Ramamurthy Gopalakrishnan; Shruti Shah; Lisa Bauer; Ketan B Ghaghada; Christopher Hoimes; Susann M Brady-Kalnay; James P Basilion; Mark A Griswold; Efstathios Karathanasis
Journal:  Cancer Res       Date:  2015-01-27       Impact factor: 12.701

4.  Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.

Authors:  Yuan-Bo Pan; Chi-Hao Zhang; Si-Qi Wang; Peng-Hui Ai; Kui Chen; Liang Zhu; Zhao-Liang Sun; Dong-Fu Feng
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

5.  Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase.

Authors:  Jonathan T Butcher; Russell A Norris; Stanley Hoffman; Corey H Mjaatvedt; Roger R Markwald
Journal:  Dev Biol       Date:  2006-10-04       Impact factor: 3.582

Review 6.  Periostin and TGF-β-induced protein: Two peas in a pod?

Authors:  Deane F Mosher; Mats W Johansson; Mary E Gillis; Douglas S Annis
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-08-10       Impact factor: 8.250

7.  Targeted in vivo extracellular matrix formation promotes neovascularization in a rodent model of myocardial infarction.

Authors:  Shirley S Mihardja; Dongwei Gao; Richard E Sievers; Qizhi Fang; Jinjin Feng; Jianming Wang; Henry F Vanbrocklin; James W Larrick; Manley Huang; Michael Dae; Randall J Lee
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

8.  TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Authors:  Marta Irigoyen; María J Pajares; Jackeline Agorreta; Mariano Ponz-Sarvisé; Elisabeth Salvo; María D Lozano; Ruben Pío; Ignacio Gil-Bazo; Ana Rouzaut
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

9.  Proteomic profiling of TGFBI-null mouse corneas reveals only minor changes in matrix composition supportive of TGFBI knockdown as therapy against TGFBI-linked corneal dystrophies.

Authors:  Ebbe Toftgaard Poulsen; Kasper Runager; Nadia Sukusu Nielsen; Marie V Lukassen; Karen Thomsen; Paige Snider; Olga Simmons; Henrik Vorum; Simon J Conway; Jan J Enghild
Journal:  FEBS J       Date:  2017-11-23       Impact factor: 5.542

10.  Inhibition of human scleral fibroblast cell attachment to collagen type I by TGFBIp.

Authors:  Lilian Shelton; Jody A Summers Rada
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-22       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.